166 related articles for article (PubMed ID: 30895706)
1. Long-term impact of diabetes in patients with ST-segment elevation myocardial infarction: Insights from the EXAMINATION randomized trial.
Jimenez-Quevedo P; Brugaletta S; Cequier A; Iñiguez A; Serra A; Mainar V; Campo G; Tespili M; Nombela-Franco L; Del Trigo M; Gonzalo N; Escaned J; Salinas P; Nuñez-Gil I; Fernandez-Perez C; Fernández-Ortiz A; Macaya C; Serruys PW; Sabate Tenas M
Catheter Cardiovasc Interv; 2019 Dec; 94(7):917-925. PubMed ID: 30895706
[TBL] [Abstract][Full Text] [Related]
2. The EXAMINATION trial (Everolimus-Eluting Stents Versus Bare-Metal Stents in ST-Segment Elevation Myocardial Infarction): 2-year results from a multicenter randomized controlled trial.
Sabaté M; Brugaletta S; Cequier A; Iñiguez A; Serra A; Hernádez-Antolín R; Mainar V; Valgimigli M; Tespili M; den Heijer P; Bethencourt A; Vázquez N; Backx B; Serruys PW
JACC Cardiovasc Interv; 2014 Jan; 7(1):64-71. PubMed ID: 24332423
[TBL] [Abstract][Full Text] [Related]
3. Comparison of newer-generation drug-eluting with bare-metal stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of the EXAMINATION (clinical Evaluation of the Xience-V stent in Acute Myocardial INfArcTION) and COMFORTABLE-AMI (Comparison of Biolimus Eluted From an Erodible Stent Coating With Bare Metal Stents in Acute ST-Elevation Myocardial Infarction) trials.
Sabaté M; Räber L; Heg D; Brugaletta S; Kelbaek H; Cequier A; Ostojic M; Iñiguez A; Tüller D; Serra A; Baumbach A; von Birgelen C; Hernandez-Antolin R; Roffi M; Mainar V; Valgimigli M; Serruys PW; Jüni P; Windecker S
JACC Cardiovasc Interv; 2014 Jan; 7(1):55-63. PubMed ID: 24332419
[TBL] [Abstract][Full Text] [Related]
4. Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: the BVS-EXAMINATION Study (bioresorbable vascular scaffold-a clinical evaluation of everolimus eluting coronary stents in the treatment of patients with ST-segment elevation myocardial infarction).
Brugaletta S; Gori T; Low AF; Tousek P; Pinar E; Gomez-Lara J; Scalone G; Schulz E; Chan MY; Kocka V; Hurtado J; Gomez-Hospital JA; Münzel T; Lee CH; Cequier A; Valdés M; Widimsky P; Serruys PW; Sabaté M
JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt B):189-197. PubMed ID: 25616924
[TBL] [Abstract][Full Text] [Related]
5. Everolimus-eluting stent versus bare-metal stent in elderly (≥75 years) versus non-elderly (<75 years) patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: insights from the examination trial.
Ielasi A; Brugaletta S; Silvestro A; Cequier A; Iñiguez A; Serra A; Hernandez-Antolin R; Mainar V; Valgimigli M; den Heijer P; Bethencourt A; Vazquez N; Serruys P; Sabate M; Tespili M
Int J Cardiol; 2015 Jan; 179():73-8. PubMed ID: 25464418
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes of contemporary drug-eluting stents in patients with and without diabetes mellitus: Multigroup propensity-score analysis using data from stent-specific, multicenter, prospective registries.
Kwon O; Lee JB; Ahn JM; Kang SJ; Lee SW; Kim YH; Lee CW; Park SW; Park DW; Park SJ;
Catheter Cardiovasc Interv; 2020 Aug; 96(2):243-252. PubMed ID: 31478593
[TBL] [Abstract][Full Text] [Related]
7. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.
Serruys PW; Farooq V; Kalesan B; de Vries T; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Wijns W; Morice MC; Di Mario C; Corti R; Antoni D; Sohn HY; Eerdmans P; Rademaker-Havinga T; van Es GA; Meier B; Jüni P; Windecker S
JACC Cardiovasc Interv; 2013 Aug; 6(8):777-89. PubMed ID: 23968698
[TBL] [Abstract][Full Text] [Related]
8. 10-Year Follow-Up of Patients With Everolimus-Eluting Versus Bare-Metal Stents After ST-Segment Elevation Myocardial Infarction.
Brugaletta S; Gomez-Lara J; Ortega-Paz L; Jimenez-Diaz V; Jimenez M; Jiménez-Quevedo P; Diletti R; Mainar V; Campo G; Silvestro A; Maristany J; Flores X; Oyarzabal L; De Miguel-Castro A; Iñiguez A; Serra A; Nombela-Franco L; Ielasi A; Tespili M; Lenzen M; Gonzalo N; Bordes P; Tebaldi M; Biscaglia S; Rodriguez-Arias JJ; Al-Shaibani S; Arevalos V; Romaguera R; Gomez-Hospital JA; Serruys PW; Sabaté M
J Am Coll Cardiol; 2021 Mar; 77(9):1165-1178. PubMed ID: 33663733
[TBL] [Abstract][Full Text] [Related]
9. Everolimus Eluting Stents in Patients with Diabetes Mellitus and Chronic Kidney Disease: Insights from the TUXEDO Trial.
Bangalore S; Abhaichand R; Mullasari A; Jain R; Chand RKP; Arambam P; Kaul U
Cardiovasc Revasc Med; 2019 Dec; 20(12):1075-1080. PubMed ID: 31036397
[TBL] [Abstract][Full Text] [Related]
10. Second-versus first-generation "Limus"-eluting stents in diabetic patients with coronary artery disease: a randomized comparison in setting of ISAR-TEST-4 trial.
Kufner S; Byrne RA; Mehilli J; Massberg S; Birkmeier KA; Schulz S; Pache J; Schömig A; Kastrati A
Catheter Cardiovasc Interv; 2013 Nov; 82(6):E769-76. PubMed ID: 23754254
[TBL] [Abstract][Full Text] [Related]
11. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
Dangas GD; Serruys PW; Kereiakes DJ; Hermiller J; Rizvi A; Newman W; Sudhir K; Smith RS; Cao S; Theodoropoulos K; Cutlip DE; Lansky AJ; Stone GW
JACC Cardiovasc Interv; 2013 Sep; 6(9):914-22. PubMed ID: 24050859
[TBL] [Abstract][Full Text] [Related]
12. The efficacy of everolimus-eluting stent implantation in patients with ST-segment elevation myocardial infarction: outcomes of 2-year clinical follow-up.
Yano H; Horinaka S; Ishikawa M; Ishimitsu T
Heart Vessels; 2016 Oct; 31(10):1609-15. PubMed ID: 26686370
[TBL] [Abstract][Full Text] [Related]
13. Randomized comparison of everolimus-eluting stents and sirolimus-eluting stents in patients with ST elevation myocardial infarction: RACES-MI trial.
Di Lorenzo E; Sauro R; Varricchio A; Capasso M; Lanzillo T; Manganelli F; Carbone G; Lanni F; Pagliuca MR; Stanco G; Rosato G; Suryapranata H; De Luca G
JACC Cardiovasc Interv; 2014 Aug; 7(8):849-56. PubMed ID: 25147029
[TBL] [Abstract][Full Text] [Related]
14. Everolimus-eluting stent versus bare metal stent in proximal left anterior descending ST-elevation myocardial infarction: insights from the EXAMINATION trial.
Gomez-Lara J; Brugaletta S; Gomez-Hospital JA; Ferreiro JL; Roura G; Romaguera R; Martin-Yuste V; Masotti M; Iñiguez A; Serra A; Hernandez-Antolin R; Mainar V; Valgimigli M; Tespili M; den Heijer P; Bethencourt A; Vazquez N; Serruys P; Sabate M; Cequier A
Am Heart J; 2013 Jul; 166(1):119-26. PubMed ID: 23816030
[TBL] [Abstract][Full Text] [Related]
15. Five-Year Optical Coherence Tomography in Patients With ST-Segment-Elevation Myocardial Infarction Treated With Bare-Metal Versus Everolimus-Eluting Stents.
Gomez-Lara J; Brugaletta S; Jacobi F; Ortega-Paz L; Ñato M; Roura G; Romaguera R; Ferreiro JL; Teruel L; Gracida M; Martin-Yuste V; Freixa X; Masotti M; Gomez-Hospital JA; Sabate M; Cequier A
Circ Cardiovasc Interv; 2016 Oct; 9(10):. PubMed ID: 27702766
[TBL] [Abstract][Full Text] [Related]
16. Staged complete revascularization or culprit-only percutaneous coronary intervention for multivessel coronary artery disease in patients with ST-segment elevation myocardial infarction and diabetes.
Cui K; Lyu S; Liu H; Song X; Yuan F; Xu F; Zhang M; Wang W; Zhang M; Zhang D; Tian J
Cardiovasc Diabetol; 2019 Sep; 18(1):119. PubMed ID: 31530274
[TBL] [Abstract][Full Text] [Related]
17. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).
Gada H; Kirtane AJ; Newman W; Sanz M; Hermiller JB; Mahaffey KW; Cutlip DE; Sudhir K; Hou L; Koo K; Stone GW
JACC Cardiovasc Interv; 2013 Dec; 6(12):1263-6. PubMed ID: 24239202
[TBL] [Abstract][Full Text] [Related]
18. Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial.
Sabate M; Cequier A; Iñiguez A; Serra A; Hernandez-Antolin R; Mainar V; Valgimigli M; Tespili M; den Heijer P; Bethencourt A; Vazquez N; Gómez-Hospital JA; Baz JA; Martin-Yuste V; van Geuns RJ; Alfonso F; Bordes P; Tebaldi M; Masotti M; Silvestro A; Backx B; Brugaletta S; van Es GA; Serruys PW
Lancet; 2012 Oct; 380(9852):1482-90. PubMed ID: 22951305
[TBL] [Abstract][Full Text] [Related]
19. Impact of stent overlapping on long-term clinical outcomes in patients with ST-segment elevation myocardial infarction: insights from the five-year follow-up of the EXAMINATION trial.
Ortega-Paz L; Brugaletta S; Giacchi G; Ishida K; Cequier A; Iñiguez A; Serra A; Jiménez-Quevedo P; Mainar V; Campo G; Tespili M; den Heijer P; Valgimigli M; Serruys PW; Sabaté M
EuroIntervention; 2017 Aug; 13(5):e557-e563. PubMed ID: 28242584
[TBL] [Abstract][Full Text] [Related]
20. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
